NASDAQ : EYPT
EyePoint, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.38 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 32.76M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 31.02M |
| Enterprise Value | -127.09M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 86.21M |
| Shares Outstanding | 86.21M |
| Shares Change (YoY) | +25.93% |
| Shares Change (QoQ) | +0.63% |
| Owned by Insiders (%) | 0.94% |
| Owned by Institutions (%) | 96.95% |
| Float | 60.67M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.77 |
| Forward PS | 31.37 |
| PB Ratio | 0.18 |
| P/TBV Ratio | 0.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.50 |
| Quick Ratio | 4.30 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9,605.33 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -148.70% |
| Return on Assets (ROA) | -74.85% |
| Return on Invested Capital (ROIC) | -86.42% |
| Return on Capital Employed (ROCE) | -170.19% |
| Weighted Average Cost of Capital (WACC) | 7.79% |
| Revenue Per Employee | $13,028 |
| Profits Per Employee | -$1.43M |
| Employee Count | 214 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 114.15 |
Taxes
| Measure | Value |
|---|
| Income Tax | 136,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.68 |
| 52-Week Price Change | -97.26% |
| 50-Day Moving Average | 3.11 |
| 200-Day Moving Average | 10.91 |
| Relative Strength Index (RSI) | 16.01 |
| Average Volume (20 Days) | 17,986,393 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 21.26M |
| Short Previous Month | 20.79M |
| Short % of Shares Out | 24.66% |
| Short % of Float | 35.04% |
| Short Ratio (days to cover) | 6.38 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.79M |
| Gross Profit | -257.47M |
| Operating Income | -316.98M |
| Pretax Income | -306.51M |
| Net Income | -306.64M |
| EBITDA | -314.38M |
| EBIT | -316.98M |
| Loss Per Share | -$3.76 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 180.47M |
| Total Debt | 22.37M |
| Net Cash | 158.11M |
| Net Cash Per Share | $1.83 |
| Equity (Book Value) | 166.41M |
| Book Value Per Share | 1.96 |
| Working Capital | 146.87M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -267.30M |
| Capital Expenditures | -3.98M |
| Depreciation & Amortization | 2.60M |
| Net Borrowing | -111,000 |
| Free Cash Flow | -271.28M |
| FCF Per Share | -$3.15 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -11,369.30% |
| Pretax Margin | -10,993.79% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -25.93% |
| Shareholder Yield | -25.93% |
| Earnings Yield | -1,046.19% |
| FCF Yield | -903.17% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.44 |
| Price Target Difference | 2,245.19% |
| Analyst Consensus | Hold |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 53.38% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 9, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.28 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |